Abgeschlossene Studien AML
AIDA2009
Empfehlung zur risikoadaptierten Behandlung der akuten Promyelozytenleukämie (APL) im Rahmen der AML-SAL-Studiengruppe (AIDA2009) - eine Beobachtungsstudie; Prof. Dr. G. Ehninger, Universitätsklinikum Dresden
AML-AZA
A randomized, multi-center phase II trial to assess the efficacy of 5-Azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML; Prof. Dr. C. Müller-Tidow, Universitätsklinikum Halle
AML96
Risikoadaptierte und randomisierte Induktions- und Postremissionstherapie der akuten myeloische Leukämie des Erwachsenen; Prof. Dr. G. Ehninger, Universitätsklinikum Dresden
AML2003
Randomisierter Vergleich zwischen Standard- und intensivierter Therapiestrategie der akuten myeloischen Leukämie des Erwachsenen im Alter von <= 60 Jahren; Prof. Dr. G. Ehninger, Universitätsklinikum Dresden
APL0406
A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagno-sed, non high-risk acute promyelocytic leukaemia; Prof. Dr. U. Platzbecker, Universiätsklinikum Dresden
APOLLO
A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLine-based chemotherapy (AIDA regimen) for patients with newLy diagnosed, high-risk acute promyelocytic leukemia
ASAP-ETAL3
Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML - A phase-III study on the comparison of two treatment strategies for patients with high-risk acute myeloid leukemia by the Study Alliance Leukemia (SAL)
BLAST
A double-blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 Addition to conSolidation Therapy in AML patients; Prof. Dr. C. Müller-Tidow, Universitätsklinikum Halle
BRIDGE
Clofarabine salvage therapy in patients with relapsed or refractory acute myeloid leukemia; Prof. Dr. J. Schetelig, Universitätsklinikum Dresden
DaunoDouble
Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia <= 60 years
DELTA
A randomized placebo-controlled phase 2 study of decitabine/azacitidine with or without eltrombopag in AML patients ≥65 years of age not eligible for intensive chemotherapy
GnG
Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in older patients with newly diagnosed AML
Konditionierung AML in 1. CR
Randomisierte Phase III Studie zum Vergleich von intensiver und dosisreduzierter Konditionierung vor allogener peripherer Blutstammzelltransplantation bei patienten mit AML in 1. kompletter Remission; Prof. Dr. M. Bornhäuser, Universitätsklinikum Dresden
MIDOKIT
A single-arm phase II trial to assess the efficacy of midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML; Prof. Dr. C. Röllig, Universiätsklinikum Dresden
Q-HAM
Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD
RATIFY (PKC)
A phase III randomized, double-blind study of induction (Daunorubicin/Cytarabine) and consolidation (High-Hose Cytarabine) chemotherapy + Midostaurin (PKC412) (IND # 101261) or placebo in newly diagnosed patients <60 years of age with FLT3 mutated Acute Myeloid Leukemia (AML); Prof. Dr. C. Röllig, Universiätsklinikum Dresden
RELAX
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (RELAX)
RELAZA02
Behandlung des drohenden hämatologischen Rezidives von Patienten mit MDS oder AML mit Azacitidin (Vidaza) Eine prospektive, offene, einarmige, multizentrische Phase II Studie; Prof. Dr. U. Platzbecker, Universiätsklinikum Dresden
SORAML
A double-blind, placebo-controlled, randomized, multicenter phase-II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML <=60 years of age; Prof. Dr. G. Ehninger, Universitätsklinikum Dresden
SORMAIN
A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after allogenic stem cell transplantation; Prof. Dr. A. Burchert, Universiätsklinikum Marburg
TEAM Protokoll V1.1
TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach
TORAML
Eine doppelblinde, plazebo-kontrollierte, randomisierte, multizentrische Phase II Studie zur Erfassung der Wirksamkeit von Temsirolimus zusätzlich zur Standard-Erstlinienchemotherapie bei Patienten >60 Jahre mit neudiagnostizierter AML; Dr. C. Brandts, Universitätsklinikum Frankfurt